1	An autosomal dominant cardiac arrhythmia syndrome, ST Depression					
2	Syndrome, is caused by the <i>de novo</i> creation of a cardiomyocyte enhancer.					
3						
4	Carin P. de Villiers <sup>1†</sup> , Damien J. Downes <sup>2†</sup> , Anuj Goel <sup>1,3</sup> , Alistair T. Pagnamenta <sup>3</sup> , Elizabeth					
5	Ormondroyd <sup>1</sup> , Alexander J. Sparrow <sup>1</sup> , Svanhild Nornes <sup>4,5</sup> , Edoardo Giacopuzzi <sup>3,6</sup> , Phalguni					
6	Rath <sup>3</sup> , Ben Davies <sup>3</sup> , Ron Schwessinger <sup>2,7</sup> , Matthew E. Gosden <sup>2</sup> , Robert A. Beagrie <sup>3,8</sup> ,					
7	Duncan Parkes <sup>3</sup> , Rob Hastings <sup>1</sup> , Stefano Lise <sup>3,9</sup> , Silvia Salatino <sup>3</sup> , Hannah					
8	Roberts <sup>3</sup> , Maria Lopopolo <sup>3</sup> , Carika Weldon <sup>3</sup> , Amy Trebes <sup>3</sup> , The WGS500 consortium <sup>10</sup> ,					
9	David Buck <sup>3</sup> , Jenny C. Taylor <sup>3</sup> , Charles Redwood <sup>1</sup> , Edward Rowland <sup>11</sup> , Dushen					
10	Tharmaratnam <sup>12</sup> , Graham Stuart <sup>13</sup> , Pier D. Lambiase <sup>11</sup> , Sarah De Val <sup>4,5</sup> , Jim R. Hughes <sup>2,7</sup> *,					
11	Hugh Watkins <sup>1,3</sup> *					
12						
13	<sup>†</sup> These authors contributed equally: Carin P. de Villiers & Damien J. Downes.					
14	*Corresponding authors: <u>hugh.watkins@rdm.ox.ac.uk</u> , jim.hughes@imm.ox.ac.uk					
15						
16	Affiliations:					
17	1	Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of				
18		Oxford, Oxford, UK				
19	2	MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine,				
20		Radcliffe Department of Medicine, University of Oxford, Oxford, UK				
21	3	Centre for Human Genetics, University of Oxford, Oxford, UK				
22	4	Ludwig Institute for Cancer Research Ltd, Nuffield Department of Medicine,				
23		University of Oxford, Oxford, UK				
24	5	Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK				
25	6	Human Technopole, Milan, Italy				
26	7	MRC WIMM Centre for Computational Biology, MRC Weatherall Institute of				
27		Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford,				
28		UK				
29	8	Laboratory of Gene Regulation, MRC Weatherall Institute of Molecular Medicine,				
30		Radcliffe Department of Medicine, University of Oxford, Oxford, UK				
31	9	University College London Cancer Institute, London, UK				
32	10	Contributors listed at the end of the manuscript				
33	11	St Bartholomew's Hospital, Barts Health NHS Trust, London, UK and UCL Institute of				
34		Cardiovascular Science, University College London, London, UK				
35	12	Royal Devon University Healthcare NHS Foundation Trust				

- 36 13 Bristol Heart Institute, Bristol, United Kingdom
- 37 38
- 39 **Keywords:** Enhancer, KCNB1, ECG, ST-segment, Arrhythmia, Mendelian disease,
- 40 gene regulation, machine learning

## 41 Abstract

- 42 A substantial proportion of mutations underlying rare Mendelian diseases remain unknown,
- 43 potentially because they lie in the non-coding genome. Here, we report the mapping of the
- 44 causal mutation of an autosomal dominant cardiac arrhythmia syndrome, ST Depression
- 45 Syndrome, which is associated with widespread ST-depression on the electrocardiogram
- together with risk of sudden death and heart failure, to the non-coding region of the KCNB1
- 47 locus. Using genetic linkage analysis, we narrowed the associated region to 1cM of the
- 48 genome and then with a genome editing approach, we show that the mutation, a small
- 49 complex insertion-deletion, generates a *de novo* gain-of-function enhancer that drives higher
- 50 expression of *KCNB1* in cardiomyocytes. This is the first report of a gain of *de novo*
- 51 enhancer function causing Mendelian disease. Critically, the tissue-specific gain-of-function
- 52 regulatory change could be predicted using a deep neural network. Application of a similar
- 53 framework will enable identification of causal non-coding mutations and affected genes in
- 54 other rare diseases.

# 55 Introduction

56

57 In the last decade, advances in sequencing technologies have produced a wealth of data for 58 understanding the causes of Mendelian disease, however, variant interpretation and 59 identification of disease-causing mutations is still incomplete. Current approaches detect a pathogenic variant in only a third of patients with suspected genetic disease<sup>1-4</sup>, with the vast 60 61 majority of them located in the coding part of the genome. Candidate gene panels, whole 62 exome sequencing (WES), and certain bioinformatic variant filtering approaches using whole 63 genome sequencing (WGS) data<sup>5</sup>, still frequently miss or disregard non-coding variants. This 64 is partly due to a huge gap in knowledge concerning these parts of the genome. However, iust as the majority of common disease variants are thought to affect regulatory, rather than 65 coding sequence<sup>6</sup>, there are likely to be a number of primary disease-causing mutations 66 67 affecting non-coding regulatory elements that are currently going undetected<sup>7</sup>. Additionally, 68 within efforts to define disease-causing non-coding variants, most emphasis is on detecting 69 variants that disrupt annotated regulatory elements, with few efforts directed at detecting 70 newly created elements and gain-of-function changes. Bridging this gap in knowledge 71 requires better understanding of the mechanisms of non-coding mutations underlying 72 heritable disease, along with improved tools to predict and characterise these changes. 73 74 We previously reported a novel inherited cardiac arrhythmia syndrome with widespread ST-75 segment depression on the electrocardiogram (ECG), termed here ST Depression 76 Syndrome (STDS)<sup>8</sup>. This syndrome is inherited in an autosomal dominant manner and 77 predisposes affected individuals to life-threatening arrhythmias; however, the primary 78 disease-causing mutation remained unknown<sup>9</sup>. Genome-wide association studies (GWAS) for variation in ECG segments, including the PR<sup>10</sup>, QRS<sup>11</sup>, QT<sup>12,13</sup> and ST<sup>14</sup> intervals, have 79 80 all highlighted the role of non-coding variants in the electrophysiology of the heart. Here we 81 report a rare non-coding mutation, shared as a founder allele by affected STDS families, as 82 the underlying genetic cause of this novel cardiac arrhythmia syndrome. By applying a 83 machine-learning, genome-engineering and multi-omics approach developed for the deciphering of GWAS variants<sup>15,16</sup>, we show that the causal mutation, a complex insertion-84 85 deletion, repurposes the sequence of a skeletal muscle enhancer to generate a *de novo* 86 gain-of-function cardiomyocyte enhancer that drives increased expression in the heart of the 87 nearby potassium voltage-gated channel encoding gene, KCNB1. To our knowledge, this is 88 the first report of a *de novo* enhancer causing Mendelian disease.

### 89 Results

90

## 91 Clinical findings in families with ST-depression on the ECG

92 A total of 14 individuals from five UK families (Fig. 1b) were identified as having autosomal 93 dominant ST Depression Syndrome (STDS) (Fig. 1a). Family 1 was described in the original 94 report of this syndrome (Family B in reference 8), with widespread ST-segment depression 95 on the ECG, starting in childhood then stable through life, with incidences of ventricular 96 arrhythmia resulting in cardiac arrest, and atrial fibrillation (AF) and ventricular contractile 97 impairment developing in later life. The proband of Family 2, IV-4, presented with ventricular 98 arrhythmia in mid-adult life and was noted to have widespread ST-segment depression; an 99 implantable cardioverter-defibrillator (ICD) was implanted when she was in her early thirties. 100 In her 50s and 60s she received multiple ICD shocks for symptomatic polymorphic 101 ventricular tachycardia. She died in her early 60s with severe left ventricular (LV) systolic 102 impairment with an ejection fraction of 10%. Two distant relatives, both in their 30s, were 103 found to have the same ECG phenotype: the ECG features were found in IV:1 when he was 104 investigated for chest pain but found to have normal coronary arteries and then in IV:2, who 105 has no symptoms, on family screening. Neither have had significant arrhythmias. Their 106 father (III:1) died in his mid 60s, with 'abnormal ECG' noted in clinical records but no other 107 information available. The proband of Family 3, also in his 30s, had the abnormal ECG 108 features detected during an insurance medical, had a structurally normal heart and no 109 arrhythmias. His mother had died suddenly in her early 70s with a history of AF, dilated 110 cardiomyopathy and ST-segment depression reported on her ECG. The proband in Family 4 111 presented with syncope as a young adult and was found to have the typical ECG changes of 112 widespread, persistent ST-segment depression. Cardiac MRI was normal and no arrhythmia 113 has been documented on an implanted loop recorder. Her mother died suddenly in her early 114 50s with a clinical record of "sudden cardiac death" but no post-mortem analysis. The 115 proband in Family 5 presented with paroxysmal AF in her 50s. Her sinus rhythm ECGs 116 showed fixed changes typical of familial STDS. Her CT coronary angiogram demonstrated 117 no coronary artery disease, and subsequent cardiac MRI was normal. Her daughter has an 118 identical ECG and is asymptomatic with normal cardiac MRI. 119 120 Distantly related families with a shared disease locus in a small segment on

### 121 chromosome 20

122 To identify regions of interest, independent linkage analyses were performed for each of the

123 two larger families, using data generated from single nucleotide polymorphism (SNP) arrays

6

124 (Family 1: II:1, II:3, II:5, III:1, III:3, III:4, III:5, III:6, IV:1 and IV:2, Family 2: III:5, IV:4, IV:5 and 125 V:1) and WGS (Family 2: IV:1). For Family 1, two regions of the genome on chromosomes 126 12 and 20 showed complete linkage (LOD = 2.41) with ST-segment depression (Fig. 2a, 127 Supplementary Table 1); all other chromosomal regions were excluded with LOD < -2.0. 128 Family 2 did not share the linkage region on chromosome 12, but an overlapping region 129 showing perfect segregation (hg38, chr20:48,212,554-50,048,337, LOD = 1.52) was 130 detected on chromosome 20 (Fig. 2a, Supplementary Table 1), indicating that these two 131 families likely share a single causative locus. 132 133 To explore the possibility that these two STDS families could be distantly related we next 134 examined informative SNPs from the array genotyping to define the haplotypes segregating 135 with disease in the regions of complete linkage in each of Family 1 and 2. In Family 1, this 136 revealed a 6.29 Mbp (10.74cM) segment carried by each of the 7 affected members and not 137 carried by the unaffected family members (Fig. 2b, Supplementary Fig. 1a,b). In Family 2, 138 haplotype analysis revealed a 1.01 Mbp (1.02 cM) region similarly showing complete linkage 139 with STDS, delimited by recombination events within the family (Fig. 2b, Supplementary Fig. 140 1c,d). The haplotypes in this shared region of complete linkage were identical in Family 1 141 and Family 2.-Inspection of this haplotype shows that it is rare, carried by 0.006% of 142 European ancestry individuals in UKBiobank (Supplementary Fig. 2). Thus, this finding 143 provides robust evidence that this sharing has not arisen by chance, but rather Family 1 and 144 2 are distantly related, i.e. share a common ancestor, such that this shared region is 145 identical-by-descent (IBD). Confirmation of a shared IBD region allows linkage data from the 146 two families to be combined for estimation of minimal LOD score; this gives a combined 147 LOD of 4.26 (Fig. 2a).

148

149 In Family 3, whole genome sequence data was available on the proband, but not SNP array 150 data. Genotypes were therefore extracted for informative SNPs in the linkage region on 151 chromosome 20. This revealed an ~ 4.3 Mbp segment in which the disease-associated 152 allele in the risk haplotype in Family 1 was always present in the Family 3 proband's 153 genotype. To estimate the probability that this might have arisen by chance, we examined 154 SNPs not in LD with one another across this region and calculated the combined likelihood 155 of carriage of at least one copy of the relevant allele. This showed that the probability that 156 this might have arisen by chance in less than  $2.3 \times 10^{-05}$ , again indicating that this segment 157 has been passed down IBD from a common ancestor. Taken together these analyses 158 indicate that the disease locus in these families lies on chromosome 20 within the small 159 ~1Mbp region defined by the extent of the IBD segment and haplotype shared by all three.

#### 160

### 161 Affected family members share a single non-coding variant

- 162 Variant calling and quality-based filtering with Platypus<sup>17</sup>, using whole genome sequence
- 163 data for the six affected individuals from families 1, 2 and 3, resulted in an aggregated
- 164 dataset containing 6,926,029 variants (6,133,943 SNPs and 792,086 indels). Of these
- variants, there were 22 novel heterozygous variants shared by the 6 selected affected
- 166 individuals that were absent from both the general population (gnomAD and 1000G) and the
- 167 control cohort (Supplementary Table 2). None of these variants affected coding sequence
- 168  $\,$  and only one was in the region defined by genetic linkage and the extended area of IBD and
- 169 haplotype sharing. This variant was a single, small, complex deletion and insertion located in
- 170  $\,$  the ~1Mbp shared region on chromosome 20 and carried on the shared affected haplotype
- $171 \qquad (see \ Supplementary \ Table \ 3): \ NC\_000020.11: \ g.49356862-49356878 delins \ TCCC, \ i.e.$
- 172 comprising loss of 17 residues and gain of four others, referred to hereafter as delinsTCCC
- 173 (Fig. 3). The delinsTCCC variant was absent in all databases searched, including gnomAD
- 174 and the 100KGP project.
- 175
- 176 Sanger sequencing was used to confirm that this variant was absent in unaffected relatives
- 177 (n=4, Family 1: III:6, Family 2: III:5, IV:5 and V:1) and present in all affected cases from
- 178 families 1, 2 and 3 (n=12, Family 1: II:1, II:3, III:3, III:4, III:5, IV:1 and IV:2, Family 2: IV:1,
- 179 IV:2 and IV:4, Family 3: II:1). Finally, Sanger sequencing revealed that the same
- 180 delinsTCCC was present in both probands from the two additional families subsequently
- 181 ascertained, Families 4 & 5.

182

## 183 In silico analysis of the delinsTCCC variant

184 The delinsTCCC variant lies in a highly conserved intergenic region of the genome, 6,999 bp

- 185 downstream of the nearest annotated gene, the potassium channel encoding gene KCNB1
- 186 (Fig. 3) and 78.8 kbp upstream of the nearest transcription start site (*ZNFX1*). Given the
- 187 non-coding location of this variant we reasoned this region could play a role in transcriptional
- 188 regulation of genes influencing the ST-segment. Consistent with this hypothesis, it is
- 189 positioned within 50 kbp of two independent sentinel SNPs identified by a GWAS for ST-
- 190 segment amplitude<sup>14</sup> (Fig. 4 and Supplementary Dataset 1). Application of a platform
- 191 designed to decode GWAS signals<sup>15,16</sup> by considering regulatory, splicing and coding
- 192 mechanisms, attributed these signals to two moderately linked candidate causal variants
- 193 (rs6012624, rs6019764, r<sup>2</sup>: 0.715 [EUR]), which both lie in open chromatin in
- 194 cardiomyocytes. Using a deep convolutional neural network (CNN)<sup>15,18</sup> trained to predict cell
- 195 type-specific chromatin activity from sequence we predicted that both GWAS variants alter

chromatin accessibility in cardiomyocytes (Supplementary Dataset 1). Published low-

196

8

197 resolution (20 kbp) chromosome conformation capture (3C) Hi-C data from cardiomyocytes 198 differentiated from induced pluripotent stem cells (iPSC) and embryonic stem cells (ESC)<sup>19</sup> 199 shows that one of the predicted causal GWAS variants and the delinsTCCC variant lie in a 200 region of chromatin that interacts with the KCNB1 promoter, but not the ZNFX1 promoter 201 (Fig. 4a). These results suggest that altered gene regulation at this locus can affect the ST-202 segment and may be responsible for STDS. 203 204 Given the sequence conservation surrounding the delinsTCCC variant and the nearby 205 predicted regulatory GWAS SNPs, we investigated Assay for Transposase-Accessible Chromatin-sequencing (ATAC-seq) data from ESC derived cardiomyocyte progenitors<sup>19</sup> and 206 207 iPSC derived cardiomyocytes from unaffected individuals<sup>20</sup>, and single cell ATAC-seq (scATAC-seq) from developing embryonic heart<sup>21</sup> for the presence of open chromatin, which 208 209 is associated with enhancers. This analysis revealed that the delinsTCCC site does not lie in 210 a region of open chromatin in cardiac cells (Fig. 4a and Fig. 5a) with the nearest open 211 chromatin located ~12 kbp upstream; given the Hi-C chromatin structure we named this site 212 E-139 as it is a putative enhancer and 139 kbp from the KCNB1 promoter (Fig. 5a, 213 Supplementary Fig. 3). A broader survey of 95 ENCODE DNase1-seq open chromatin 214 datasets<sup>22,23</sup> and 126 developmental scATAC-seq datasets<sup>21</sup> shows this region is accessible 215 in skeletal muscle cells and multiple carcinomas (Supplementary Fig. 4) and is designated 216 as a distal enhancer like sequence by ENCODE. Recent work has shown how sequence 217 changes in enhancers can lead to loss of tissue-specificity by optimizing transcription factor binding affinity; including for cardiac enhancers that regulate ECG traits<sup>24,25</sup>. Given the 218 219 chromatin accessibility in non-cardiac muscle cells and the nearby ST-segment GWAS 220 signal we hypothesized delinsTCCC may lead to a change in enhancer tissue-specificity, to 221 generate a cryptic de novo cardiomyocyte enhancer. Supportive of this hypothesis, the 222 predictions from the deep CNN found that delinsTCCC had the potential to increase 223 chromatin accessibility in cardiomyocytes and smooth muscle cells but not in carcinomas 224 (Fig. 5b, Supplementary Fig. 5). In silico mutagenesis of each base pair across the 225 delinsTCCC region showed that a TCCC motif (Fig. 5c), corresponding to several 226 transcription factor families, was important for the predicted gain in accessibility. Consistent 227 with binding-affinity optimization, both ETS and NFKB showed stronger motif matches to the 228 variant sequence than to reference sequence; whereas the E2F motif is only found in the 229 variant sequence (Fig. 5d). These findings strengthen the evidence for this disease-causing 230 variant while supporting the hypothesis for a *de novo* cardiomyocyte enhancer. 231

#### 9

# 232 delinsTCCC generates a cardiac enhancer

233 To test if delinsTCCC generates an open chromatin site in human cardiomyocytes, we 234 generated iPSC lines (Supplementary Fig. 6) heterozygous for the delinsTCCC variant using 235 CRISPR-Cas9 genome editing (Supplementary Fig. 7). ATAC-seq in cardiomyocytes 236 differentiated from these iPSC showed the presence of a *de novo* open chromatin element 237 which contained the delinsTCCC variant (Fig. 5a). Allelic analysis of reads in this region 238 indicated that over 84% of the reads came from the mutated allele, implying that the peak 239 was specific to the delinsTCCC sequence (Supplementary Fig. 7). Relative levels of histone 240 H3 lysine-4 mono- and tri-methylation (H3K4me1, H3K4me3) can be used to distinguish 241 enhancers and promoters<sup>26</sup>. We performed Cleavage Under Targets and Release Using 242 Nuclease (CUT&RUN)<sup>27</sup> for both H3K4me1, which is primarily at enhancers, and H3K4me3. 243 which is primarily at promoters, in the heterozygous mutant cardiomyocyte cells. Higher 244 levels of H3K4me1 relative to H3K4me3 were detected at the *de novo* element and E-139 245 (Fig. 5a, Supplementary Fig. 8), consistent with ENCODE ChIP-seq for these marks in 246 smooth muscle cells (Supplementary Fig. 4), indicating that they are both likely to be 247 enhancers.

248

249To determine if the delinsTCCC sequence and the E-139 element function as enhancers we250placed each, as well as the equivalent wild-type sequence for the delinsTCCC site (WT),

separately upstream of the silent E1b minimal promoter and a GFP reporter gene and

generated Tol2-induced transgenic zebrafish embryos. Both the *tg*(*E-139:GFP*) and the

*tg(delinsTCCC:GFP)* transgenic fish showed strong GFP expression in the heart, spread

throughout the ventricles in a fairly consistent manner (Fig. 6a,b, Supplementary Table 4).

By comparison, the *tg(WT:GFP)* transgenic fish displayed low or negligible GFP expression

in this region. Expression in certain other parts of the fish (e.g. the eye) was in keeping with

commonly observed autofluorescence (Supplementary Fig. 9).

258

In addition to the heart, the *tg*(*E*-139:*GFP*) fish also displayed strong expression in other parts of the fish including the head (Fig. 6c, Supplementary Fig. 10). Consistently, E-139

261 was accessible in numerous cerebrum cell-types in ATAC-seq from developing human

brains<sup>21</sup> (Supplementary Fig. 3). This is interesting as the closest gene, *KCNB1*, is known to

263 play a significant role in the brain<sup>28</sup>. Therefore, while the E-139 element appears to be

264 involved in more ubiquitous expression, the delinsTCCC variant seems to specifically drive

265 gene expression in the heart.

266

## 267 delinsTCCC drives higher *KCNB1* expression in cardiomyocytes

268 To identify the target gene(s) of the *de novo* delinsTCCC enhancer, we generated high-269 resolution 3C interaction profiles for the three closest active genes (KCNB1, ZNFX1, PTGIS) with nuclear-titrated Capture-C<sup>29</sup> using wild-type and heterozygous delinsTCCC iPSC 270 271 derived cardiomyocytes. Capture-C from the KCNB1 promoter in the wild-type cells showed 272 strong interaction with E-139 and a proximal CTCF site (C-150) situated 150 kbp upstream 273 of the promoter (Fig. 7). Neither ZNFX1 nor PTGIS showed strong interaction with this 274 region (Supplementary Fig. 11). Capture-C from *KCNB1* in heterozygous delinsTCCC cells, 275 showed significantly higher levels of interaction with fragments covering E-139 compared to 276 the wild-type cells (Fig. 7; two-sided Wilcoxon matched-pairs signed rank test, p<0.0001). To 277 exclude the possibility that these elements interact with more distal genes, we next 278 performed Capture-C experiments from both the delinsTCCC enhancer and E-139. The 279 delinsTCCC site did not show a strong interaction with the KCNB1 promoter, nor any other 280 promoter, in either wild-type or heterozygous cells. The E-139 enhancer interacted 281 specifically with the KCNB1 promoter and the level of interaction was significantly increased 282 in the presence of the delinsTCCC allele (two-sided Wilcoxon matched-pairs signed rank 283 test, p=0.0094).

284

Finally, to determine whether the increased E-139/*KCNB1* interaction in the presence of the delinsTCCC variant led to higher gene expression, we performed quantitative real-time PCR experiments using iPSC derived cardiomyocytes. Three independent heterozygous clones (C6, C68 and C93), each with multiple differentiations, collectively showed markedly increased *KCNB1* expression (two-sided Mann-Whitney test, p=0.0015) (Fig. 8a).

290

291 To investigate differences in allelic expression, we identified a SNP (rs2229006) within the 292 coding sequence of KCNB1 (exon 2, NM 004975.4) that was heterozygous in the parental 293 iPSC cell line. By combining public phase data and Nanopore sequencing we determined 294 that the variant allele, rs2229006-C, was in *cis* with the edited delinsTCCC allele in clone C6 295 (Supplementary Fig. 12). RNA sequencing showed a bias for KCNB1 transcripts arising from 296 the chromosome containing the delinsTCCC variant, with the rs2229006-C allele being 3.8-297 fold more abundant than the reference rs2229006-G allele (Supplementary Table 5). These 298 findings corroborate a mechanism whereby a *de novo* enhancer, created by the delinsTCCC 299 variant, leads to cardiac specific KCNB1 upregulation through an increased interaction 300 between E-139 and the *KCNB1* promoter (Fig. 8b).

# 301 Discussion

302

303 We have utilised a multi-omics, genome engineering and machine learning<sup>15,16</sup> approach to 304 identify and characterise a novel gain-of-function non-coding disease-causing variant 305 responsible for a recently described cardiac arrhythmia syndrome, STSD<sup>8,30</sup>. This syndrome 306 is associated with widespread ST-segment depression on the ECG and predisposes 307 affected individuals to cardiac events including sudden cardiac death and heart failure. The 308 responsible variant, delinsTCCC, generates a cryptic cardiomyocyte enhancer which drives 309 higher expression of the potassium channel encoding gene, KCNB1. 310 311 Cardiac arrhythmia syndromes are most commonly associated with variants in ion channel 312 genes<sup>31</sup>. Consistent with this, the causal variant identified in this study enhances the 313 expression in the heart of the KCNB1-encoded, pore-forming subunit of the voltage-gated 314 potassium channel Kv2.1. This channel acts as a delayed rectifier, propagating current in a 315 wide range of electrically active cell types across many organ systems. Kv2.1 plays an important role in the repolarisation phase of the action potential in rodent hearts<sup>32,33</sup>, is 316 expressed in human atrial<sup>34-36</sup> and ventricular cells<sup>35,36</sup>, and binds ion channel beta-subunits 317 318 from the KCNE family<sup>37</sup> known to contribute to other cardiac arrhythmia syndromes such as 319 the Long-QT syndrome<sup>38,39</sup>. However, rather than causing cardiac disease, pathogenic 320 KCNB1 coding variants have been shown to cause neurological disorders, specifically forms 321 of developmental and epileptic encephalopathy<sup>40</sup>. Much attention has been devoted to the 322 study of Kv2.1 in the human brain, largely due to its high expression in this region<sup>41</sup>. 323 Interestingly, our study identified the regulatory element proximal to the delinsTCCC 324 enhancer, E-139, as an interactor of the KCNB1 gene promoter and we confirm its ability of 325 driving reporter gene expression in zebrafish brain. The broad clinical spectrum of subjects 326 with different KCNB1 variants emphasises the cell-type specific impact of regulatory 327 changes which determine which organs are affected, and hence the phenotypes of these 328 inherited conditions.

329

The hallmark phenotype of resting ST-segment depression on the surface ECG in STDS implies transmural heterogeneity of currents underlying the cardiac action potential, thereby creating a transmural gradient (analogous to the ST-segment shifts seen acutely in the context of subendocardial ischaemia or myocardial infarction)<sup>42,43</sup>. Therefore, we hypothesise that the delinsTCCC enhancer results in differential increases in KCNB1 expression, and hence Kv2.1 activity, in different layers of the myocardium – a property commonly associated with cardiac ion channels<sup>44</sup>. A shorter endocardial action potential,

12

337 induced by an endocardial increase in expression of the Kv2.1 channel, would promote 338 current flow from epicardial sites with longer action potentials to generate ST depression on 339 the surface ECG. This is the inverse of the gradient seen in Brugada Syndrome which 340 promotes localised ST elevation associated with different transmural action potential 341 durations where the epicardial action potential duration is relatively short <sup>45,46</sup>. These 342 gradients require electrotonic uncoupling to be maintained. Indeed, the fact that the ST 343 depression develops 80ms after the J point would be compatible with such differences 344 developing in phase 3 and 4 of the action potential when Kv2.1 is active. Such gradients set 345 up potential sites for phase 2 re-entry following an ectopic beat initiating the polymorphic 346 ventricular arrhythmias described in this rare familial condition<sup>47</sup>.

347

348 The delinsTCCC variant underlying STDS adds to the growing knowledge of non-coding 349 regulatory variants associated with ECG traits. Previous reports, including a number of GWAS<sup>10-14</sup>, have identified non-coding regions important for the ST<sup>14</sup>, QT<sup>12,13,48-50</sup>, PR<sup>10,51-53</sup> 350 and QRS<sup>11,51–53</sup> intervals. However, identifying specific target genes and their associated 351 352 functional effects is still a huge challenge. This has limited the detection and inclusion of 353 pathogenic non-coding variants in clinical practice. Furthermore, while pairing genes to their 354 regulatory elements can be carried out using a combination of chromosome conformation 355 capture techniques<sup>54</sup> and open chromatin atlases<sup>21</sup>, these methods are of little use for the 356 identification of *de novo* enhancer variants. Therefore, our study highlights the value of 357 combining these rich resources with ongoing 'classic' family studies, cellular models and 358 machine learning to improve non-coding variant detection and validation.

359

360 Gain-of-function mechanisms are an important consideration when trying to decipher non-361 coding effects. Despite reports of gain-of-function variants within existing enhancers in 362 common disease, rare disease and malignancy<sup>55–57</sup>, we believe this is the first description of 363 an entirely de novo cryptic enhancer causing a Mendelian disorder. Variants creating de 364 novo regulatory elements may conceivably be more common than expected. Recently, a 365 single nucleotide variant which causes  $\alpha$ -thalassemia was fully characterised as generating 366 a gain-of-function cryptic promoter which blocks interaction between the two  $\alpha$ -globin encoding genes and their cognate enhancers<sup>58</sup>. Additionally, in T-cell acute lymphoblastic 367 368 leukaemia, gain-of-function deletions upstream of the TAL1 oncogene generate a de novo enhancer which drives higher gene expression<sup>59</sup>. Similarly, in several autosomal dominant 369 heritable diseases, including brachydactyly-anonychia<sup>60</sup>, Keratolytic Winter Erythema<sup>61</sup>, 370 Haas-type polysyndactyly and Laurin-Sandrow syndrome<sup>62</sup>, as well as syndactyly and 371

13

372 craniosynostosis<sup>63</sup>, duplications of developmental gene enhancers cause disease through
 373 gain-of-function.

374

375 Intriguingly, our 3C approach did not detect significant changes in the interaction between 376 the *de novo* cryptic enhancer and the *KCNB1* promoter. This suggests that the delinsTCCC 377 enhancer may function in an indirect manner, by promoting stronger interaction between E-378 139 and the KCNB1 promoter. Recent work to dissect the role of the five independent 379 elements of the mouse alpha-globin super enhancer has shown that while some elements 380 look like classical tissue-specific enhancers in reporter assays, they instead act as facilitators for nearby enhancers in their native context<sup>64</sup>. This is consistent with the tissue-381 382 specific GFP expression driven by the delinsTCCC enhancer in the Zebrafish reporter 383 assay. This mechanism is compatible with two current models for gene regulation. In the first model, the loop extrusion model<sup>65</sup>, the delinsTCCC enhancer could be recruiting additional 384 385 cohesin<sup>66</sup>, promoting an increase in the frequency of the interaction between KCNB1 and E-386 139. In contrast to this model, the second involves an increase in bound transcription factors leading to more frequent or stable phase-separation<sup>67</sup>. Further research is required to better 387 388 understand these models and their contribution to disease. 389

In addition to specific cardiovascular conditions, including cardiac arrythmias<sup>8</sup>, ischemia or coronary heart disease<sup>68</sup>, ST-segment depression on the ECG is associated with an increased risk of unexplained sudden cardiac death in the general population<sup>69</sup>. GWAS have identified numerous common variants that are associated with ST-segment variability<sup>14</sup>, some of which are near the delinsTCCC variant. Therefore, additional studies of non-coding variants associated with ECG alterations from both GWAS and Mendelian disease will likely improve our general understanding of both gene regulation and cardiovascular disease.

398

# 399 Acknowledgements

- The authors are grateful to Nadav Ahituv from the University of California, San Francisco for
  gifting the E1b-GFP-Tol2 vector. We would also like to thank Charlotte Ives, Inherited
  Arrhythmia Clinical Nurse Specialist, Barts Health NHS Trust, London, and Ellie Quinn from
  Royal Brompton and Harefield Hospitals for assistance with patient records. Additionally, we
  would like to thank the Oxford Genomics Centre at the Centre for Human Genetics for the
  generation and initial processing of sequencing data.
  This work was supported by funding from the British Heart Foundation (BHF), Wellcome
- 407 This work was supported by funding from the billish flear foundation (bill), wellcome
- 408 Trust (nos.090532/Z/09/Z and 203141/Z/16/Z to H.W.) and the National Institute for Health
- 409 Research (NIHR) Oxford Biomedical Research Centre. The views expressed are those of
- 410 the authors and not necessarily those of the NHS, the NIHR or the Department of Health or
- 411 Wellcome Trust. J.R.H received funding from a Wellcome Strategic Award (no.
- 412 106130/Z/14/Z), Wellcome Discovery Award (225220/Z/22/Z) and Medical Research Council
- 413 Core Funding (no. MC\_UU\_00016/14 and MC\_UU\_00029/3). R.S. was supported by a
- 414 Wellcome Doctoral Programme (no. 203728/Z/16/Z). R.A.B was funded by a Sir Henry
- 415 Wellcome Fellowship (no. 209181/Z/17/Z). S.D. and S.N. were supported by a BHF
- 416 Fellowship (no. FS/1735/32929), MRC project grant (no. MR/S01019X/1) and by Leducq
- 417 Foundation grant 18CVD03. P.L. was supported by UCL/UCLH and Barts NIHR Biomedical
- 418 Research Centres. H.W.'s laboratory is supported by the British Heart Foundation's Big Beat
- 419 Challenge award to CureHeart (BBC/F/21/220106).420
- 421

#### 422 Author contributions

- 423 C.P.D.V, D.J.D., A.J.S., S.N., P.R., M.E.G., R.A.B., M.L., C.W., A.T. performed experiments.
- 424 C.P.D.V, D.J.D., A.T.P., A.J.S., S.N., E.G., A.G., M.F., R.S., D.P., S.L, S.S, H.R. processed
- 425 data and performed analyses.
- 426 C.P.D.V, D.J.D. designed experiments.
- 427 C.P.D.V., D.J.D., A.T.P., A.J.S., S.N, E.G., A.G., M.F., P.R, D.P. wrote the manuscript and
- 428 made figures.
- 429 E.O., R.H., E.R., G.S, P.L., H.W. collected and evaluated clinical data.
- 430 C.P.D.V, A.J.S. cultured iPSC derived cardiomyocytes.
- 431 S.N. performed zebrafish investigations.

- 432 P.R. produced CRISPR-Cas9 edited iPSC cell lines.
- 433 M.L, C.W., A.T. performed nanopore sequencing.
- 434 M.F., B.D., D.B., J.C.T., C.R., S.D.V., J.R.H., H.W. provided supervision.
- 435 H.W., J.R.H., acquired funding, oversaw the work, and revised the manuscript.
- 436 H.W. conceived the work.
- 437

# 438 Disclosures

- 439 J.R.H. is a founder, shareholder and director of Nucleome Therapeutics.
- 440 J.R.H. holds patents for Capture-C (nos. WO2017068379A1, EP3365464B1
- 441 and US10934578B2).
- 442 R.H. is currently employed at Novartis and has stock ownership for AstraZeneca and
- 443 Illumina
- 444 D.J.D. is currently employed by Blue Matter Consulting
- 445 R.S is currently employed by Glaxo-Smith Klein
- 446 The other authors declare no competing interests.





452

453 **Fig. 1. Families with ST-depression syndrome (STDS). a**, Example ECG lead II traces

454 showing normal versus ST-segment depression in affected members from five independent

455 UK families. **b**, Partial pedigrees of families identified with STDS. Affected individuals are

456 shaded in black. The full pedigrees have not been disclosed to comply with medRxiv's

457 policies. Full disclosure of the pedigrees is available upon request from the authors.





473
 474
 474
 475
 475
 476
 476
 477
 477
 478
 479
 479
 470
 470
 470
 471
 471
 472
 473
 474
 474
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475
 475

476 PhastCons conservation predictions using 100 vertebrates.

477



- 482 interaction plots for ESC and iPSC derived cardiomyocytes, ATAC-seq peaks for iPSC
- 483 derived cardiomyocytes, genes and delinsTCCC location. **b**, SNPs in linkage ( $r^2 \ge 0.8$  [EUR])
- 484 with ST-segment GWAS sentinel SNPs rs11907908 (blue) and rs2202261 (red).





486 487 Fig. 5. Accessibility analysis of the delinsTCCC variant sequence. a, ATAC sequencing 488 analysis of published data (GSE89895, GSE106690) for cardiomyocytes (CM) and 489 progenitors, including mesoderm (MES) and cardiac progenitors (CP), derived from 490 differentiation of embryonic stem cells (ESC), or induced pluripotent stem cells (iPSC). 491 Cardiomyocytes either lacked (WT) or were heterozygous (delinsTCCC/WT) for the 492 delinsTCCC variant. CTCF ChIP-seq (Erythroid, GSE125926) shows tissue-invariant 493 boundary elements. H3K4me1 and H4K4me3 CUT&RUN in delinsTCCC heterozygous 494 cardiomyocytes show enhancers and promoters respectively. Inset region is

chr20:49,327,000-49,367,000 (hg38) with 5-pixel window. **b**, deep CNN accessibility

496 predictions. Error bars denote one standard deviation of accessibility score for the 13

497 possible 1 kbp sequences covering the indel site. **c**, *in silico* mutagenesis for the

- 498 delinsTCCC site indicating a possible motif including the TCCC insert. **d**, left panel shows
- the colour coded FIMO derived predicted motifs from both the reference and variant
- 500 delinsTCCC sequence. The right panel shows the PhyloP sequence conservation plotted
- 501 over the reference sequence (Ref) with the deleted sequence high-lighted in red and with
- 502 the position of motif matches and FIMO p-values below. The delins TCCC variant sequence
- 503 is shown below with the 4 base-pair insertion highted in blue and with the position of motif
- 504 matches and FIMO p-values below, showing the creation of a strong E2F7 motif and the
- 505 rearrangement and increase in scores for pre-existing motifs.



#### 506

Fig. 6. Enhancer variant expression in zebrafish embryos. a, GFP expression for
 transgenic fish containing the E-139, wild type (WT) or delinsTCCC variant sequence. The
 asterisk indicates the location of the heart. The MyI7 cardiac marker is overlaid in red. DIC =
 differential interference contrast. b, Total GFP levels observed in the hearts of transgenic
 zebrafish; n represents the total number of transgenic zebrafish embryos per category. c, E-

512 139 transgenic fish displayed strong expression in the brain indicated by the arrows.

23



516

**Fig. 7. Chromatin conformation and interaction assays.** ATAC sequencing analysis of experimental data from iPSC derived cardiomyocytes (CM) heterozygous (delinsTCCC/WT) for the delinsTCCC variant. CTCF ChIP-seq shows boundary elements. Capture-C from the *KCNB1* promoter, delinsTCCC enhancer, and the E-139 enhancer. Solid lines show mean (n=3 independent samples) with one standard deviation (shading). Subtraction tracks show per *Dpn*II fragment difference. Enhancer and promoter regions indicated below display regions of significant difference.



524

525 Fig. 8. KCNB1 upregulation by the delinsTCCC variant. a, Fold change in KCNB1

526 expression versus the housekeeping gene (GAPDH) detected by qPCR for reference (WT

527 n=4 independent samples/differentiations) and heterozygous delinsTCCC clones (C6 n=3,

528 C68 n=4, C93 n=4 independent samples/differentiations). The mean for each group is

529 represented by the black horizontal line, bars show standard error of the mean and the p-

value from two-sided Mann-Whitney test is indicated. **b**, Model illustrating a proposed

531 regulatory mechanism with the delinsTCCC variant indirectly enhancing KCNB1

532 transcription.

# 533 References

- 534 1. Taylor, J. C. et al. Factors influencing success of clinical genome sequencing across a
- 535 broad spectrum of disorders. *Nat. Genet.* **47**, 717–726 (2015).
- 536 2. Trujillano, D. et al. Clinical exome sequencing: results from 2819 samples reflecting 1000
- 537 families. *Eur. J. Hum. Genet.* **25**, 176–182 (2017).
- 538 3. Wright, C. F., FitzPatrick, D. R. & Firth, H. V. Paediatric genomics: diagnosing rare disease
- 539 in children. *Nat. Rev. Genet.* **19**, 253–268 (2018).
- 540 4. Lee, H. *et al.* Diagnostic utility of transcriptome sequencing for rare Mendelian diseases.
- 541 Genet. Med. 22, 490–499 (2020).
- 542 5. Gloss, B. S. & Dinger, M. E. Realizing the significance of noncoding functionality in
- 543 clinical genomics. *Exp. Mol. Med.* **50**, 97 (2018).
- 544 6. Maurano, M. T. *et al.* Systematic localization of common disease-associated variation in
- 545 regulatory DNA. *Science* **337**, 1190–1195 (2012).
- 546 7. French, J. D. & Edwards, S. L. The Role of Noncoding Variants in Heritable Disease.
- 547 Trends Genet. **36**, 880–891 (2020).
- 548 8. Bundgaard, H. et al. A novel familial cardiac arrhythmia syndrome with widespread ST-
- 549 segment depression. *N. Engl. J. Med.* **379**, 1780–1781 (2018).
- 550 9. Christensen, A. H. & Bundgaard, H. The Novel Familial ST-Depression Syndrome -
- 551 Current Knowledge and Perspectives. *Card. Electrophysiol. Clin.* **15**, 343–348 (2023).
- 552 10. Ntalla, I. *et al.* Multi-ancestry GWAS of the electrocardiographic PR interval identifies
- 553 202 loci underlying cardiac conduction. *Nat. Commun.* **11**, 1–12 (2020).
- 554 11. Sotoodehnia, N. *et al.* Common variants in 22 loci are associated with QRS duration and
- 555 cardiac ventricular conduction. *Nat. Genet.* **42**, 1068–1076 (2010).

- 556 12. Newton-Cheh, C. et al. Common variants at ten loci influence QT interval duration in the
- 557 QTGEN Study. *Nat. Genet.* **41**, 399–406 (2009).
- 13. Pfeufer, A. *et al.* Common variants at ten loci modulate the QT interval duration in the
- 559 QTSCD Study. *Nat. Genet.* **41**, 407–414 (2009).
- 560 14. Verweij, N. *et al.* Twenty-eight genetic loci associated with ST-T-wave amplitudes of the
- 561 electrocardiogram. *Hum. Mol. Genet.* **25**, 2093–2103 (2016).
- 562 15. Downes, D. J. *et al.* An integrated platform to systematically identify causal variants and
- 563 genes for polygenic human traits. *Prepr. BioRxiv* https://doi.org/10.1101/813618 (2019).
- 16. Downes, D. J. *et al.* Identification of LZTFL1 as a candidate effector gene at a COVID-19
- 565 risk locus. *Nat. Genet.* **53**, 1606–1615 (2021).
- 566 17. Rimmer, A. *et al.* Integrating mapping-, assembly-and haplotype-based approaches for
- 567 calling variants in clinical sequencing applications. *Nat. Genet.* **46**, 912–918 (2014).
- 568 18. Schwessinger, R. *et al.* DeepC: predicting 3D genome folding using megabase-scale
- 569 transfer learning. Nat. Methods 1–7 (2020).
- 570 19. Bertero, A. *et al.* Dynamics of genome reorganization during human cardiogenesis reveal
- an RBM20-dependent splicing factory. *Nat. Commun.* **10**, 1–19 (2019).
- 572 20. Banovich, N. E. *et al.* Impact of regulatory variation across human iPSCs and
- 573 differentiated cells. *Genome Res.* **28**, 122–131 (2018).
- 574 21. Domcke, S. *et al*. A human cell atlas of fetal chromatin accessibility. *Science* **370**,
- 575 eaba7612 (2020).
- 576 22. ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human
- 577 genome. *Nature* **489**, 57–74 (2012).

- 578 23. ENCODE Project Consortium *et al.* Expanded encyclopaedias of DNA elements in the
- 579 human and mouse genomes. *Nature* **583**, 699–710 (2020).
- 580 24. Farley, E. K. *et al.* Suboptimization of developmental enhancers. *Science* **350**, 325–328
- 581 (2015).
- 582 25. Jindal, G. A. et al. Single-nucleotide variants within heart enhancers increase binding
- affinity and disrupt heart development. *Dev. Cell* 58, 2206-2216.e5 (2023).
- 584 26. Kowalczyk, M. S. *et al.* Intragenic Enhancers Act as Alternative Promoters. *Mol. Cell* **45**,
- 585 447–458 (2012).
- 586 27. Skene, P. J. & Henikoff, S. An efficient targeted nuclease strategy for high-resolution
- 587 mapping of DNA binding sites. *eLife* **6**, e21856 (2017).
- 588 28. Murakoshi, H. & Trimmer, J. S. Identification of the Kv2.1 K+ Channel as a Major
- 589 Component of the Delayed Rectifier K+ Current in Rat Hippocampal Neurons. J.
- 590 *Neurosci.* **19**, 1728–1735 (1999).
- 591 29. Downes, D. J. *et al.* High-resolution targeted 3C interrogation of cis -regulatory element
- 592 organization at genome-wide scale. *Nat. Commun.* **12**, 531 (2021).
- 593 30. Christensen, A. H. et al. Electrocardiographic Findings, Arrhythmias, and Left Ventricular
- 594 Involvement in Familial ST-Depression Syndrome. *Circ. Arrhythm. Electrophysiol.* **15**,
- 595 e010688 (2022).
- 596 31. Hedley, P. L. *et al.* The genetic basis of long QT and short QT syndromes: A mutation
- 597 update. *Hum. Mutat.* **30**, 1486–1511 (2009).
- 598 32. Xu, H. *et al.* Attenuation of the slow component of delayed rectification, action potential
- 599 prolongation, and triggered activity in mice expressing a dominant-negative Kv2  $\alpha$
- 600 subunit. *Circ. Res.* **85**, 623–633 (1999).

- 601 33. Zhou, J. *et al.* Regional upregulation of Kv2. 1-encoded current, IK, slow2, in Kv1DN mice
- is abolished by crossbreeding with Kv2DN mice. Am. J. Physiol.-Heart Circ. Physiol. 284,
- 603 H491–H500 (2003).
- 604 34. Van Wagoner, D. R., Pond, A. L., McCarthy, P. M., Trimmer, J. S. & Nerbonne, J. M.
- 605 Outward K+ current densities and Kv1. 5 expression are reduced in chronic human atrial
- 606 fibrillation. *Circ. Res.* **80**, 772–781 (1997).
- 607 35. Gaborit, N. *et al.* Regional and tissue specific transcript signatures of ion channel genes
- in the non-diseased human heart. J. Physiol. **582**, 675–693 (2007).
- 609 36. Ördög, B. *et al.* Gene expression profiling of human cardiac potassium and sodium
- 610 channels. *Int. J. Cardiol.* **111**, 386–393 (2006).
- 611 37. McCrossan, Z. A., Roepke, T. K., Lewis, A., Panaghie, G. & Abbott, G. W. Regulation of the
- 612 Kv2. 1 potassium channel by MinK and MiRP1. J. Membr. Biol. **228**, 1–14 (2009).
- 613 38. Splawski, I., Tristani-Firouzi, M., Lehmann, M. H., Sanguinetti, M. C. & Keating, M. T.
- 614 Mutations in the hminK gene cause long QT syndrome and suppress lKs function. *Nat.*
- 615 Genet. **17**, 338–340 (1997).
- 616 39. Abbott, G. W. *et al.* MiRP1 Forms IKr Potassium Channels with HERG and Is Associated
- 617 with Cardiac Arrhythmia. *Cell* **97**, 175–187 (1999).
- 618 40. Kang, S. K. *et al.* Spectrum of KV2.1 Dysfunction in KCNB1-Associated
- 619 Neurodevelopmental Disorders. *Ann. Neurol.* **86**, 899–912 (2019).
- 620 41. Trimmer, J. S. Subcellular Localization of K+ Channels in Mammalian Brain Neurons:
- 621 Remarkable Precision in the Midst of Extraordinary Complexity. *Neuron* **85**, 238–256
- 622 (2015).

623	3 42. Hopenfeld, B., Stinstra, J. G. & Macleod, R. S. N	Mechanism for ST depression associated
-----	---	--

- 624 with contiguous subendocardial ischemia. J. Cardiovasc. Electrophysiol. 15, 1200–1206
- 625 (2004).
- 626 43. Okada, J.-I. et al. Ionic mechanisms of ST segment elevation in electrocardiogram during
- 627 acute myocardial infarction. J. Physiol. Sci. JPS **70**, 36 (2020).
- 44. Schram, G., Pourrier, M., Melnyk, P. & Nattel, S. Differential Distribution of Cardiac Ion
- 629 Channel Expression as a Basis for Regional Specialization in Electrical Function. *Circ. Res.*
- 630 **90**, 939–950 (2002).
- 631 45. Bhar-Amato, J. et al. Pharmacological Modulation of Right Ventricular Endocardial-
- 632 Epicardial Gradients in Brugada Syndrome. *Circ. Arrhythm. Electrophysiol.* **11**, e006330
- 633 (2018).
- 634 46. Antzelevitch, C. The Brugada syndrome: ionic basis and arrhythmia mechanisms. J.
- 635 *Cardiovasc. Electrophysiol.* **12**, 268–272 (2001).
- 636 47. Yan, G.-X., Lankipalli, R. S., Burke, J. F., Musco, S. & Kowey, P. R. Ventricular
- 637 repolarization components on the electrocardiogram: cellular basis and clinical
- 638 significance. J. Am. Coll. Cardiol. 42, 401–409 (2003).
- 639 48. Kapoor, A. *et al.* An enhancer polymorphism at the cardiomyocyte intercalated disc
- 640 protein NOS1AP locus is a major regulator of the QT interval. Am. J. Hum. Genet. 94,
- 641 **854–869 (2014)**.
- 642 49. Kapoor, A. *et al.* Multiple SCN5A variant enhancers modulate its cardiac gene expression
- 643 and the QT interval. *Proc. Natl. Acad. Sci.* **116**, 10636–10645 (2019).
- 50. De Villiers, C. P. *et al.* AKAP9 is a genetic modifier of congenital long-QT syndrome type
- 645 1. Circ. Cardiovasc. Genet. 7, 599–606 (2014).

- 646 51. Holm, H. *et al.* Several common variants modulate heart rate, PR interval and QRS
- 647 duration. *Nat. Genet.* **42**, 117 (2010).
- 52. Bezzina, C. R. *et al.* Common Sodium Channel Promoter Haplotype in Asian Subjects
- 649 Underlies Variability in Cardiac Conduction. *Circulation* **113**, 338–344 (2006).
- 650 53. van Weerd, J. H. *et al.* Trait-associated noncoding variant regions affect TBX3 regulation
- 651 and cardiac conduction. *eLife* **9**, e56697 (2020).
- 652 54. Davies, J. O. J., Oudelaar, A. M., Higgs, D. R. & Hughes, J. R. How best to identify
- 653 chromosomal interactions: a comparison of approaches. *Nat. Methods* **14**, 125–134
- 654 (2017).
- 55. Gupta, R. M. *et al.* A Genetic Variant Associated with Five Vascular Diseases Is a Distal
- 656 Regulator of Endothelin-1 Gene Expression. *Cell* **170**, 522-533.e15 (2017).
- 657 56. Mika, K. M., Li, X., DeMayo, F. J. & Lynch, V. J. An Ancient Fecundability-Associated
- 658 Polymorphism Creates a GATA2 Binding Site in a Distal Enhancer of HLA-F. *Am. J. Hum.*
- 659 *Genet.* **103**, 509–521 (2018).
- 57. Wright, J. B., Brown, S. J. & Cole, M. D. Upregulation of c-MYC in cis through a Large
- 661 Chromatin Loop Linked to a Cancer Risk-Associated Single-Nucleotide Polymorphism in
- 662 Colorectal Cancer Cells. *Mol. Cell. Biol.* **30**, 1411–1420 (2010).
- 58. Bozhilov, Y. K. *et al.* A gain-of-function single nucleotide variant creates a new promoter
- which acts as an orientation-dependent enhancer-blocker. *Nat. Commun.* **12**, 3806
- 665 (2021).
- 59. Mansour, M. R. *et al.* An oncogenic super-enhancer formed through somatic mutation
  of a noncoding intergenic element. *Science* 346, 1373–1377 (2014).

- 668 60. Kurth, I. *et al.* Duplications of noncoding elements 5<sup>1</sup>/<sub>2</sub> of SOX9 are associated with
- brachydactyly-anonychia. *Nat. Genet.* **41**, 862–863 (2009).
- 670 61. Ngcungcu, T. et al. Duplicated Enhancer Region Increases Expression of CTSB and
- 671 Segregates with Keratolytic Winter Erythema in South African and Norwegian Families.
- 672 Am. J. Hum. Genet. **100**, 737–750 (2017).
- 673 62. Lohan, S. *et al.* Microduplications encompassing the Sonic hedgehog limb enhancer ZRS
- are associated with Haas-type polysyndactyly and Laurin-Sandrow syndrome. *Clin*.
- 675 Genet. **86**, 318–325 (2014).
- 676 63. Will, A. J. *et al.* Composition and dosage of a multipartite enhancer cluster control
- 677 developmental expression of Ihh (Indian hedgehog). *Nat. Genet.* **49**, 1539–1545 (2017).
- 678 64. Blayney, J. W. et al. Super-enhancers include classical enhancers and facilitators to fully
- 679 activate gene expression. *Cell* **186**, 5826-5839.e18 (2023).
- 680 65. Fudenberg, G. *et al.* Formation of Chromosomal Domains by Loop Extrusion. *Cell Rep.*
- 681 **15**, 2038–2049 (2016).
- 682 66. Rinzema, N. J. et al. Building Regulatory Landscapes: Enhancer Recruits Cohesin to
- 683 Create Contact Domains, Engage CTCF Sites and Activate Distant Genes.
- 684 2021.10.05.463209 https://www.biorxiv.org/content/10.1101/2021.10.05.463209v1
- 685 (2021) doi:10.1101/2021.10.05.463209.
- 686 67. Hnisz, D., Shrinivas, K., Young, R. A., Chakraborty, A. K. & Sharp, P. A. A Phase Separation
- 687 Model for Transcriptional Control. *Cell* **169**, 13–23 (2017).
- 688 68. Hanna, E. B. & Glancy, D. L. ST-segment depression and T-wave inversion: Classification,
- differential diagnosis, and caveats. *Cleve. Clin. J. Med.* **78**, 404–414 (2011).

32

690	69. Deng, XQ., Xu, XJ.,	Wu, SH., Li, H. & Cheng,	YJ. Association I	between resting painless

- 691 ST-segment depression with sudden cardiac death in middle-aged population: A
- 692 prospective cohort study. Int. J. Cardiol. **301**, 1–6 (2020).
- 693
- 694

# 695 WGS500 Consortium membership: names and affiliations of authors

- 696 Steering Committee: Peter Donnelly (Chair)<sup>1</sup>, John Bell<sup>2</sup>, David Bentley<sup>3</sup>, Gil McVean<sup>1</sup>,
- 697 Peter Ratcliffe<sup>1</sup>, Jenny C. Taylor<sup>1,4</sup>, Andrew Wilkie<sup>4,5</sup>
- 698 Operations Committee: Peter Donnelly (Chair)<sup>1</sup>, John Broxholme<sup>1</sup>, David Buck<sup>1</sup>, Jean-
- 699 Baptiste Cazier<sup>1</sup>, Richard Cornall<sup>1</sup>, Lorna Gregory<sup>1</sup>, Julian Knight<sup>1</sup>, Gerton Lunter<sup>1</sup>, Gil
- 700 McVean<sup>1</sup>, Jenny C. Taylor<sup>1,4</sup>, Ian Tomlinson<sup>1,4</sup>, Andrew Wilkie<sup>4,5</sup>
- 701 Sequencing & Experimental Follow up: David Buck (Lead)<sup>1</sup>, Christopher Allan<sup>1</sup>, Moustafa
- 702 Attar<sup>1</sup>, Angie Green<sup>1</sup>, Lorna Gregory<sup>1</sup>, Sean Humphray<sup>3</sup>, Zoya Kingsbury<sup>3</sup>, Sarah Lamble<sup>1</sup>,
- <sup>703</sup> Lorne Lonie<sup>1</sup>, Alistair T. Pagnamenta<sup>1</sup>, Paolo Piazza<sup>1</sup>, Guadelupe Polanco<sup>1</sup>, Amy Trebes<sup>1</sup>
- 704 Data Analysis: Gil McVean<sup>1</sup> (Lead), Peter Donnelly<sup>1</sup>, Jean-Baptiste Cazier<sup>1</sup>, John
- 705 Broxholme<sup>1</sup>, Richard Copley<sup>1</sup>, Simon Fiddy<sup>1</sup>, Russell Grocock<sup>3</sup>, Edouard Hatton<sup>1</sup>, Chris
- 706 Holmes<sup>1</sup>, Linda Hughes<sup>1</sup>, Peter Humburg<sup>1</sup>, Alexander Kanapin<sup>1</sup>, Stefano Lise<sup>1</sup>, Gerton
- <sup>707</sup> Lunter<sup>1</sup>, Hilary C. Martin<sup>1</sup>, Lisa Murray<sup>3</sup>, Davis McCarthy<sup>1</sup>, Andy Rimmer<sup>1</sup>, Natasha
- 708 Sahgal<sup>1</sup>, Ben Wright<sup>1</sup>, Chris Yau<sup>6</sup>
- 709
- <sup>1</sup>The Centre for Human Genetics, Roosevelt Drive, Oxford, OX3 7BN, UK
- <sup>2</sup>Office of the Regius Professor of Medicine, Richard Doll Building, Roosevelt Drive,
- 712 Oxford, OX3 7LF, UK
- <sup>3</sup>Illumina Cambridge Ltd., Chesterford Research Park, Little Chesterford, Essex, CB10 1XL,
- 714 UK
- 715 <sup>4</sup>NIHR Oxford Biomedical Research Centre, Oxford, UK
- <sup>5</sup>Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford
- 717 OX3 9DS, UK
- <sup>6</sup>Imperial College London, South Kensington Campus, London, SW7 2AZ, UK